You can buy or sell AnaptysBio and other stocks, options, ETFs, and crypto commission-free!
AnaptysBio, Inc. Common Stock, also called AnaptysBio, is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Read More Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Simply Wall StMar 12
Did You Manage To Avoid AnaptysBio’s (NASDAQ:ANAB) 42% Share Price Drop?
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. Investors in AnaptysBio, Inc. (NASDAQ:ANAB) have tasted that bitter downside in the last year, as the share price dropped 42%. That’s well bellow the market return of 1.4%. AnaptysBio hasn’t been listed for long, so although we’re wary of recent listings that perform poorly, it may still prove itself with ...
Stock Price, News, & Analysis for AnaptysBio
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular p...
Yahoo FinanceMar 6
All You Need to Know About AnaptysBio, Inc. (ANAB) Rating Upgrade to Buy
AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy). AnaptysBio, Inc. (ANAB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Conse...
Expected May 7, After Hours